Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease

Fig. 5

Inhibition of tau aggregation in vitro. Recombinant wild-type (a) or P301S mutant (b) tau at 12 μM was induced to aggregate in vitro with addition of heparin in the absence or presence of either 7G6, E2814 or control IgG1 antibodies at a concentration of 8.3 μM. Over a time course of 6 days, samples of the reaction mixture were removed and incubated with Thioflavin S (ThS) and fluorescence was measured to detect aggregated tau. Data shown represent six independent experiments for each protein. A two-way ANOVA statistical analysis was performed followed by a Dunnett’s test. **** p ≤ 0.0001 7G6 or E2814 versus IgG, *** p ≤ 0.001 7G6 vs IgG for wild type protein only. Values represent mean ± SEM

Back to article page
\